Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 4/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.47 |
| ▸ | FLT4 | P35916 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425764 | 0.90 | EGFR (0.53) | EGFRKITKDR | |
| SCHEMBL20865224 | 0.82 | ENPP1 (0.45) | EGFR | |
| SCHEMBL30017110 | 0.81 | EGFR (0.66) | EGFRKITKDRSRCFGFR1 | |
| SCHEMBL1613217 | 0.81 | EGFR (0.66) | EGFRKITKDRSRCFGFR1 | |
| SCHEMBL5650362 | 0.79 | ENPP1 (0.55) | EGFRKDR | |
| SCHEMBL12431119 | 0.79 | ENPP1 (0.55) | EGFRKDR | |
| SCHEMBL5231792 | 0.78 | ENPP1 (0.48) | EGFRKDRSRCFGFR1FLT1 | |
| SCHEMBL11953079 | 0.78 | RET (0.58) | EGFRKDRSRCFGFR1FLT1 | |
| SCHEMBL5430434 | 0.77 | ENPP1 (0.54) | EGFRKDRSRCFGFR1FLT1 | |
| SCHEMBL5226819 | 0.76 | KDR (0.48) | EGFRKDRSRCFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | EGFR 1800/4885KIT 50/4885KDR 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.